Nueterra to acquire Benefit Management

Leawood, Kansas-based healthcare company Nueterra is acquiring Benefit Management, a third-party health benefits administrator based in Great Bend, Kansas with offices in Wichita, Kansas.

Advertisement

Terms of the deal were not disclosed.

The acquisition was sought shortly after Nueterra — the largest privately-held organization in the U.S. specializing in developing equity partnerships with health systems, governments, hospitals and physicians — announced it had shifted a lot of its focus to facilitating programs and services targeting the consumer population, according to a news release.

Nueterra said Benefit Management has for a long time been a Midwest leader in the development and administration of custom benefits solutions demanding flexibility and efficiency, and will be instrumental in Nueterra’s new pay-for-value strategy targeting employers and U.S.-based payers.

“Right now, Nueterra is drawing physicians and facilities together, uniting them clinically and financially into integrated networks across the country,” Nueterra Chairman Dan Tasset said in a statement. “As we do that, we’ll be in a unique position to offer bundled payments for medical conditions for commercial populations.”

 

More articles on hospital transactions and valuation issues:

26 hospital transactions and partnerships in April

AHA CEO Rich Umbdenstock defends consolidation in response to WSJ op-ed on ‘hospital monopolies’ under PPACA

Trinity Health expands network in New York

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Transactions & Valuation Issues

Advertisement

Comments are closed.